Publications by authors named "Carlos Cuenca-Barrales"
Article Synopsis
- Therapeutic burden (TB) in hidradenitis suppurativa (HS) is a key factor that may predict responses to biologic treatments, highlighting its importance in clinical decision-making.
- A study of 557 HS patients provided insights into the average TB, which was linked to factors such as older age, longer disease duration, and greater disease severity.
- Results indicate that understanding TB can help clinicians better assess when to adjust treatment strategies for HS patients based on their individual severity and treatment history.
Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study.
Dermatol Ther (Heidelb)
July 2024
Article Synopsis
- The study investigates the timing of initiating biological therapy (secukinumab) for managing hidradenitis suppurativa (HS) to improve patient outcomes.
- It involves a retrospective analysis of 67 patients who switched to secukinumab after failing previous treatments, with follow-up lasting 24 weeks to evaluate safety and effectiveness.
- Results indicate that 41.79% achieved significant improvement, and a lower therapeutic burden (fewer prior treatments) was linked to better responses, supporting the idea that earlier treatment may be beneficial.
Article Synopsis
- The research evaluates the effectiveness and safety of bimekizumab for treating hidradenitis suppurativa in real-world clinical settings.
- Significant improvements were observed in key activity scores and patient-reported outcomes after 16 weeks, with all results showing a strong statistical significance (p < 0.001).
- Bimekizumab was well-tolerated with no reported discontinuations or new safety issues, reaffirming its favorable safety profile previously seen in phase 3 clinical trials.
Article Synopsis
- The study investigates the effectiveness and safety of ultrasound-guided galvanic current (GC) treatment for hidradenitis suppurativa (HS), a chronic skin condition, in patients where traditional treatments may not be sufficient.
- Results showed that 77% of patients experienced a complete response 12 weeks post-treatment, with no serious adverse effects noted.
- Overall, the study concludes that GC is a promising and well-tolerated local treatment option for HS.
Dupilumab is an effective treatment for atopic Dermatitis® (AD) and it also restores skin barrier function. Nevertheless, early changes in epidermal barrier parameters related to sustained treatment response or treatment failure are not known. So, the objective of this study is to evaluate whether changes in skin barrier function after 16 weeks dupilumab treatment could predict sustained treatment response or treatment failure.
View Article and Find Full Text PDFShort-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study.
Dermatol Ther (Heidelb)
April 2023
Article Synopsis
- Hidradenitis suppurativa (HS) is a chronic skin condition, and secukinumab, a biologic drug, is being studied for its effectiveness and safety in treating moderate to severe cases over 16 weeks.
- A study involving 47 patients in southern Spain found that nearly 49% achieved significant clinical improvement (HiSCR) after treatment, with only a small percentage experiencing adverse effects.
- Factors such as being female, having a lower body mass index (BMI), and a lower previous treatment burden were linked to a higher likelihood of achieving the desired treatment response.
Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima-Media Thickness Reduction.
Dermatol Ther (Heidelb)
March 2023
Article Synopsis
- Hidradenitis suppurativa (HS) is associated with increased cardiovascular risk (CVR) due to inflammation, and this study investigates how adalimumab treatment affects patients' CVR.
- In a study involving 27 patients with severe HS, while overall carotid intima-media thickness (IMT) showed no significant change after 32 weeks, 40.7% of patients improved their IMT.
- The patients who improved had more classic CVR factors like dyslipidemia and diabetes, suggesting that those with higher atherosclerosis burden and less inflammation might respond better to adalimumab treatment.
Article Synopsis
- A new parameter called IHS4-55, which indicates a 55% reduction in the severity of Hidradenitis Suppurativa (HS), was validated using data from patients treated with adalimumab and placebo.
- The research aimed to externally validate the IHS4-55 in patients treated with antibiotics, assessing its correlation with the reduction of inflammatory lesions and quality of life metrics.
- Results from a study of 283 patients showed that those achieving IHS4-55 experienced significant reductions in inflammatory nodules and had a greater likelihood of improving quality of life scores, supporting its use as a key outcome measure in clinical trials.
Sexual Dysfunction and Quality of Life in Patients with Hidradenitis Suppurativa and Their Partners.
Int J Environ Res Public Health
December 2022
Article Synopsis
- Hidradenitis suppurativa (HS) is a skin disease that affects how people feel and their relationships, not just for the person with the disease but also for their partners.
- The study looked at how HS impacts patients' quality of life (QoL) and the sexual health of both patients and their partners.
- It found that both patients and their partners experience difficulties, especially in sexual function, with various factors like disease severity and body weight affecting their overall quality of life.
Background: Surgery is an essential part of hidradenitis suppurativa (HS) treatment. Understanding and reducing surgical recurrence are crucial to obtaining the best results in patients' treatment.
Objective: The aim of the study was to characterize surgical recurrences in a cohort of patients with HS treated with wide excision and second-intention healing.
Prevalence and implications of type D personality in patients with alopecia areata: A marker of quality-of-life impairment and mood status disturbances, a comparative study.
J Eur Acad Dermatol Venereol
May 2023
Introduction: Distressed personality (or Type D personality, TDp) is a personality trait that has been associated with poor quality of life in patients suffering from a variety of skin diseases such as psoriasis or urticaria. To date the potential association between Alopecia areata (AA) and TDp has not been studied. The aim of this study was to compare the prevalence of TDp between patients with AA and controls, and to analyse the impact of TDp on patients with AA regarding mood status disturbances, quality of life and sexuality.
View Article and Find Full Text PDFExploring the role of systemic immune-inflammation index and neutrophil-lymphocyte ratio in cardiovascular risk stratification for patients with hidradenitis suppurativa: A cross-sectional study.
J Dermatol
December 2022
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle that has previously been associated with a higher cardiovascular risk (CVR). Although different methods have been described for CVR stratification in HS, there is little evidence about the role of hemogram indexes in CVR in HS. Given its potential convenience, the aim of this study was to assess the role of the hemogram indexes systemic immune-inflammation index (SII) and neutrophil-lymphocyte ratio (NLR) in CVR stratification for patients with HS.
View Article and Find Full Text PDFBackground: Early detection of melanoma is one of the main diagnostic goals of dermatologists worldwide, due to the increasing incidence of the disease in our environment. However, the irruption of the SARS-CoV-2 pandemic has posed a challenge to global healthcare, forcing systems to focus their resources on the fight against COVID-19. Methods: Retrospective cohort study.
View Article and Find Full Text PDFHidradenitis suppurativa (HS) is an inflammatory chronic disease with difficult management. In some scenarios, intralesional (IL) treatments could be useful. However, the scientific evidence available is limited and heterogeneous.
View Article and Find Full Text PDFArticle Synopsis
- Adalimumab is the only FDA-approved biological treatment for hidradenitis suppurativa (HS), and recent biosimilars have made treatment more cost-effective but may pose unique switching challenges.
- A study involving 17 HS patients switched from adalimumab to a biosimilar showed mixed results, with 41.2% maintaining treatment success while others faced issues.
- The findings suggest that while switching back to the original adalimumab can resolve problems, it might also lead to decreased patient confidence in the treatment, highlighting the need for careful evaluation of switching strategies.
Skin is damaged in atopic dermatitis (AD) patients. Age is also believed to have a negative effect on epidermal barrier function. The aim of this study was to investigate skin barrier function changes with age in AD patients.
View Article and Find Full Text PDFIntroduction: Coronavirus disease 2019 (COVID-19) has increased the frequency of handwashing. There is scarce evidence regarding the impact of different hand hygiene procedures on skin barrier function in clinical practice.
Objective: To compare the impact on skin barrier function of different hand hygiene measures in healthcare workers in daily practice.
Combined versus conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis: A randomized, single-blind, prospective study.
Photodermatol Photoimmunol Photomed
July 2022
Background: Photodynamic therapy (PDT) has become one of the most effective therapies for the treatment of actinic keratosis, allowing the removal of more than one lesion in a single session. However, the pain sustained by the patient during treatment and local skin reactions can limit its use.
Objectives: To determine the efficacy and safety of combined PDT (daylight PDT followed by conventional PDT) vs conventional PDT 12 weeks after treatment.
There is a need to establish the role of antiandrogens as an alternative or concomitant therapy for hidradenitis suppurativa (HS). Thus, the objectives of this study are (1) to assess the effectiveness of oral contraceptive pills (OCPs) at week 12 in HS women, and (2) to describe the clinical profile of patients receiving oral contraceptive pills (OCPs). A prospective observational study was designed.
View Article and Find Full Text PDFFrontal fibrosing alopecia (FFA) is an emerging disease in Western countries. We present the cases of three sisters who were referred simultaneously to the Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain, in 2018. All patients suffered from at least partial frontotemporal hairline recession and eyebrow loss.
View Article and Find Full Text PDFHidradenitis suppurativa (HS) is a chronic, recurrent and debilitating inflammatory skin disease of the hair follicle that usually presents as painful, deep-seated inflamed lesions in the apocrine gland-bearing areas of the body. HS patients suffer from uncomfortable signs and symptoms, such as pain, pruritus, malodour and suppuration, which may impair patients' quality of life (QoL). Although HS patients frequently experience these signs and symptoms, they are only occasionally assessed by clinicians and, unexpectedly, the scientific evidence available is limited and heterogeneous.
View Article and Find Full Text PDFBackground And Objectives: Information about hospital admissions for skin diseases is restricted to studies describing admissions to single centers, to specific wards, or only for a few diagnoses, and there is no information about the outcomes between different wards. The aim of this research is to describe hospital admissions due to dermatological diseases.
Patients And Methods: Cross-sectional study of hospital discharges at Spanish hospitals.